|
Common name |
B-hHER2 CT26.WT | Catalog number | 322200 |
| Aliases |
ERBB2, CD340, HER-2, HER-2/neu, HER2, MLN 19, NEU, NGL, TKR1, VSCN2, erb-b2 receptor tyrosine kinase 2 |
Disease | Colon carcinoma |
|
Organism |
Mouse |
Strain | BALB/c |
| Tissue types | Colon | Tissue | Colon |
Subcutaneous tumor growth of B-hHER2 CT26.WT cells. B-hHER2 CT26.WT cells (1x105) and wild-type MC38 cells (1x105) were subcutaneously implanted into BALB/c mice (female, 6-7-week-old, n=6). Tumor volume and body weight were measured twice a week. (A) Average tumor volume. (B) Body weight. Volume was expressed in mm3 using the formula: V=0.5 X long diameter X short diameter2. Results indicate that B-hHER2 CT26.WT cells were able to establish tumors in vivo and can be used for efficacy studies. Values are expressed as mean ± SEM.
B-hHER2 CT26.WT cells were subcutaneously transplanted into BALB/c mice (n=6), and on 23 days post inoculation, tumor cells were harvested and assessed for human HER2 expression by flow cytometry. As shown, human HER2 was highly expressed on the surface of tumor cells. Therefore, B-hHER2 CT26.WT cells can be used for in vivo efficacy studies of novel HER2 therapeutics.
In vivo efficacy of anti-human HER2 antibody-drug conjugate (ADC)
+86-10-56967680
info@bbctg.com.cn